Bruce Eaton has joined Broken String Biosciences as Chairman of the Board, effective immediately. The move comes as the company aims to scale its operations and expand the commercial reach of its INDUCE-seq platform. Eaton brings three decades of experience in biotech, including leadership roles at firms like I2 Pharmaceuticals and Editas Medicine. His recent work at Editas involved overseeing a multidisciplinary team of over 100 employees and leading a strategic realignment initiative while directing the company’s R&D program in sickle cell anemia. Eaton also founded and successfully grew multiple companies, including Velocity Sciences, a biotech firm focused on advancing molecular tools for drug discovery. His experience spans operational, business development, and corporate strategy roles for both public and private companies, positioning him to address the complex challenges of scaling a gene editing platform.
Eaton is also currently an independent director at Renova Therapeutics and advises other biotech firms in gene therapy and AI drug discovery. In his new role, he will collaborate with Broken String’s leadership to develop strategies for operational growth and global commercialization of INDUCE-seq. The platform is designed to address regulatory challenges in gene editing by offering a universal method for analyzing DNA breaks across the genome.
Related: Birth Injury Lawyers
The company recently submitted an FDA Master File for INDUCE-seq, a step that could streamline the process for developers seeking to advance new therapies toward investigational new drug (IND) applications. Terry Pizzie, CEO of Broken String Biosciences, highlighted Eaton’s background in commercial strategy as essential to positioning INDUCE-seq as a standard tool for assessing off-target effects in gene editing. The submission of the FDA Master File marks a key milestone in the company’s efforts to establish INDUCE-seq as a trusted resource for therapeutic developers, enabling them to bypass redundant testing and accelerate their regulatory pathways. This aligns with the company’s broader mission to reduce the time and cost associated with bringing gene-editing therapies to clinical trials.
The appointment of Eaton follows recent leadership changes and signals a push toward broader industry adoption of its platform. The company’s strategy now includes leveraging the FDA Master File to support therapeutic developers in their regulatory pathways. By aligning with regulatory expectations through INDUCE-seq, the company seeks to reduce barriers to innovation in gene therapy, enabling researchers to focus on advancing therapeutic candidates rather than handling fragmented testing requirements. This strategic pivot shows the company’s commitment to supporting a more predictable and efficient development environment for the next generation of gene-editing therapies.
Leave a Reply